Clinical actionability of molecular targets in endometrial cancer.,Nature Reviews Cancer

当前位置： X-MOL 学术 › Nat. Rev. Cancer › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Clinical actionability of molecular targets in endometrial cancer.
Nature Reviews Cancer ( IF 72.5 ) Pub Date : 2019-08-06 , DOI: 10.1038/s41568-019-0177-x
Mary Ellen Urick ₁ , Daphne W Bell ₁

Affiliation

Endometrial cancer accounts for ~76,000 deaths among women each year worldwide. Disease mortality and the increasing number of new diagnoses make endometrial cancer an important consideration in women's health, particularly in industrialized countries, where the incidence of this tumour type is highest. Most endometrial cancers are carcinomas, with the remainder being sarcomas. Endometrial carcinomas can be classified into several histological subtypes, including endometrioid, serous and clear cell carcinomas. Histological subtyping is currently used routinely to guide prognosis and treatment decisions for endometrial cancer patients, while ongoing studies are evaluating the potential clinical utility of molecular subtyping. In this Review, we summarize the overarching molecular features of endometrial cancers and highlight recent studies assessing the potential clinical utility of specific molecular features for early detection, disease risk stratification and directing targeted therapies.

中文翻译：

子宫内膜癌分子靶点的临床可操作性。

子宫内膜癌每年导致全球约 76,000 名女性死亡。疾病死亡率和新诊断数量的增加使子宫内膜癌成为妇女健康的一个重要考虑因素，特别是在工业化国家，这种肿瘤类型的发病率最高。大多数子宫内膜癌是癌，其余是肉瘤。子宫内膜癌可分为多种组织学亚型，包括子宫内膜样癌、浆液性癌和透明细胞癌。组织学亚型目前常规用于指导子宫内膜癌患者的预后和治疗决策，而正在进行的研究正在评估分子亚型的潜在临床效用。在这篇综述中，我们总结了子宫内膜癌的总体分子特征，并重点介绍了最近的研究，这些研究评估了特定分子特征在早期检测、疾病风险分层和指导靶向治疗方面的潜在临床效用。

更新日期：2019-08-06

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南